The Securities and Exchange Commission (SEC) is considering whether to pursue enforcement against a certified public accountant for his alleged role in an accounting fraud case the agency brought against biotech company MiMedx Group in 2019.

The Securities and Exchange Commission (SEC) is considering whether to pursue enforcement against a certified public accountant for his alleged role in an accounting fraud case the agency brought against biotech company MiMedx Group in 2019.